CLS February 27th Options Begin Trading

Celestica (CLS) options present income opportunities: a $285 put is bid at $30 with the stock at $287.78, implying a net cost basis of $255 if assigned and a 59% probability of expiring worthless; that premium equates to a 10.53% return (76.84% annualized). On the call side, a $295 covered call is bid at $32.50, about 3% OTM and offering a 13.80% total return to Feb. 27 if called (11.29% boost if it expires worthless) with a 45% chance of expiring worthless. Implied volatilities are high (put 82%, call 85%) versus a 250-day trailing volatility of 81%, underscoring elevated option premiums and yield-oriented trade considerations for income-focused investors.

Analysis

Market structure: Elevated option interest in CLS benefits option premium sellers, retail income strategies and broker flow desks (collecting commissions); it pressures upside for pure equity holders because call overlays can cap rallies. The put/call strikes ($285 put/$295 call) and premiums ($30/$32.50) imply short-term buyer willingness to transact around $255–$295 effective ranges, concentrating risk within ~±12% of today's $287.78 price over the next ~4–8 weeks (Feb 27 expiry). Delta-hedging by option sellers could create short-stock flows on rallies and buy flows on dips, increasing intraday volatility around corporate catalysts.

Risk assessment: Tail risks include a large customer order loss, supply-chain disruption, or surprise FY guidance cut that could push CLS below $230 (20%+ drop) and blow up naked short-put positions; regulatory/FX shocks to manufacturing demand are second-order threats. Timewise: immediate (days) is option gamma & assignment risk; short-term (weeks) is earnings/order cadence that can spike IV (>120% from 82%); long-term (quarters) relates to electronics capex cycles and customer mix. Hidden dependency: sellers assume IV reverts to realized (~81%); if realized >100% sellers face asymmetric losses.

Trade implications: Direct tactical income: sell-to-open CLS Feb27 285 puts only if willing to be long at $255 (effective -11.4% vs today) with position size 1–3% portfolio; target realized annualized YieldBoost ~77% but limit downside with a 285/255 put spread. Conservative equity income: buy CLS and sell Feb27 295 covered calls to capture ~13.8% gross return to expiry; size 1–3% and be prepared to be called. Volatility trade: avoid naked short >1% notional; prefer short put spreads or buy 260 protective puts if net short premium.

Contrarian angles: Consensus frames this as easy yield; it understates assignment/earnings-jump risk and that IV is only mildly above realized (82–85% vs 81%), so premium may be undercompensating for skew. If CLS reports better-than-expected orders or a large customer win, call sellers will be massively squeezed — capped returns (13.8%) vs potential stock upside of 30%+. Historical parallel: semiconductor supply-cycle whipsaws show high IV periods can stay elevated for months; avoid large naked short exposure and favor defined-risk structures.

Key Decisions for Investors

• Sell-to-open CLS Feb27 285 put (collect ~$30) sized to 1–2% of portfolio only if willing to be assigned at $255; simultaneously place buy-to-open 255 put to form a 285/255 put spread to cap max loss and limit required margin (max loss ≈ $30/share).
• Establish a covered-call position: buy CLS up to 2% portfolio and sell Feb27 295 call (collect ~$32.50) to lock a 13.8% gross return to expiry; set a rule to exit the call if CLS >$330 pre-earnings or roll up if IV falls >20% from current.
• If selling premium naked, require protective hedges: convert naked put sales into defined-risk put spreads or purchase a 260 protective put per 100 contracts if net short exposure exceeds 1% portfolio; de-risk if IV rises above 120% or CLS gap-downs below $250.
• Relative trade: go long CLS (2% portfolio) and short FLEX (ticker: FLEX, equal notional) for 3 months to isolate company-specific recovery; take profits if CLS outperforms by +10 percentage points or if sector order momentum reverses.